
Abivax SA
ABVXHealthcare|Biotechnology|France
$139.90
-0.87 (-0.62%)
Tangible Book
$5.81
Earnings Power
$7.00
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
2.67,
91.92,
325.15,
751.39,
1215.04
],
"ebit_estimate": [
-284.19,
-300.61,
-159.63,
157.88,
533.71
],
"ebitda_estimate": [
-280.12,
-75.38,
413.63,
1616.05,
null
],
"net_income_estimate": [
-285.76,
-292.65,
-119.42,
133.41,
460.69
],
"per_share_eps_estimate": [
-3.51,
-3.84,
-2.05,
1.54,
5.28
],
"eps_nri_estimate": [
-3.61,
-3.86,
-1.68,
1.8,
5.28
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
7.01,
5.03,
5.48,
null,
null
],
"pretax_income_estimate": [
-283.65,
-282.84,
-130.18,
161.85,
537.99
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null
],
"roe_estimate": [
-55.7,
-44.28,
-7.24,
null,
null
],
"gross_margin_estimate": [
null,
94,
94,
94,
94
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
90.61,
26.51
],
"long_term_growth_rate_mean": 58.47,
"long_term_revenue_growth_rate_mean": "556.86",
"future_per_share_eps_estimate_growth": 58.47,
"future_eps_nri_estimate_growth": 58.47,
"future_revenue_estimate_growth": 556.86,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": 56.49,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": -7.81,
"future_operating_cash_flow_per_share_estimate_growth": null
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712",
"202803"
],
"revenue_estimate": [
0.78,
0.78,
0.8,
0.91,
0.91,
0.91,
2.92,
0.38
],
"ebit_estimate": [
-63.15,
-63.94,
-68.52,
-83.23,
-91.95,
-67.4,
-60.57,
null
],
"ebitda_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"net_income_estimate": [
-69.73,
-61.77,
-62.18,
-85.8,
-94.54,
-70.02,
-63.21,
null
],
"per_share_eps_estimate": [
-1.1,
-0.61,
-1.08,
-0.55,
-1.08,
-0.96,
-0.93,
null
],
"eps_nri_estimate": [
-1.25,
-0.66,
-1.11,
-0.98,
-1.14,
-1.32,
-1.55,
null
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pretax_income_estimate": [
-71.06,
-60.97,
-62.11,
-85.51,
-94.25,
-69.73,
-62.92,
null
],
"operating_cash_flow_per_share_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
null,
null,
null,
null,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null,
null
],
"long_term_growth_rate_mean": 58.47,
"long_term_revenue_growth_rate_mean": "556.86",
"future_per_share_eps_estimate_growth": 58.47,
"future_eps_nri_estimate_growth": 58.47,
"future_revenue_estimate_growth": 556.86,
"future_ebit_estimate_growth": null,
"future_ebitda_estimate_growth": null,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": null,
"future_pretax_income_estimate_growth": 56.49,
"future_book_value_per_share_estimate_growth": null,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": null,
"future_gross_margin_estimate_growth": -7.81,
"future_operating_cash_flow_per_share_estimate_growth": null
}